Hyundai Bioscience Co

Hyundai Bioscience Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Hyundai Bioscience Co (048410.KQ) as of Nov 1, 2026 is -21.63 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 902.20 M KRW — a change of -2,497.01% (lower).

EBITDA

-21.63 BKRW

YoY

-2,497.01%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Hyundai Bioscience Co is 2025 -21.63 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Hyundai Bioscience Co was 2024 902.20 M KRW. It decreases by -2,497.01% lower compared to the previous year.

The Hyundai Bioscience Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
2.78 B KRW
Jan 1, 2019
5.22 B KRW
Jan 1, 2020
-1.67 B KRW
Jan 1, 2021
-15.46 B KRW
Jan 1, 2022
-17.25 B KRW
Jan 1, 2023
-14.04 B KRW
Jan 1, 2024
902.20 M KRW
Jan 1, 2025
-21.63 B KRW
The Hyundai Bioscience Co EBITDA history
YEAREBITDAYoY
-21.63 BKRW-2,497.01%
902.20 MKRW-106.43%
-14.04 BKRW-18.63%
-17.25 BKRW+11.55%
-15.46 BKRW+825.49%
-1.67 BKRW-132.00%
5.22 BKRW+87.81%
2.78 BKRW+37.92%
2.02 BKRW-130.89%
-6.52 BKRW-465.95%
1.78 BKRW+56.72%
1.14 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hyundai Bioscience Co Stock analysis

What does Hyundai Bioscience Co do? Hyundai Bioscience Co., Ltd. generates revenue through the manufacturing and sale of bio-cosmetics and hair tonics, including functional daily necessities like shampoos, mask packs, and creams. The company also develops tumor-targeted drugs and sells LCD monitors and digital signage display products. Domestic and overseas markets, including Europe, America, and Japan, purchase these products, with the firm distributing its offerings across these regions. The company's product portfolio features bio-cosmetics, hair tonics, shampoos, mask packs, creams, tumor-targeted drugs, LCD monitors, and digital signage displays. These items are sold to customers in both domestic and international markets, with Europe, America, and Japan representing key overseas segments. The firm focuses on functional daily necessities and display technology products as its core revenue streams. Hyundai Bioscience Co., Ltd. targets consumers seeking bio-based personal care products and businesses requiring display solutions. Its domestic market serves local customers, while international segments in Europe, America, and Japan drive global sales. The company’s revenue model combines consumer goods sales with technology-oriented product distribution. Hyundai Bioscience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hyundai Bioscience Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Hyundai Bioscience Co is -21.63 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Hyundai Bioscience Co changed from 902.20 M KRW to -21.63 B KRW, representing a -2,497.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Hyundai Bioscience Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Hyundai Bioscience Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Hyundai Bioscience Co

All Key Metrics — Hyundai Bioscience Co